High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: A prospective cohort study

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Sacks Davis, Rachel ^a,b   Aitken, Campbell K ^a,b   Higgs, Peter ^a,c   Spelman, Tim ^a,b   Pedrana, Alisa E ^a   Bowden, Scott ^d   Bharadwaj, Mandvi ^e   Nivarthi, Usha K ^e   Suppiah, Vijayaprakash ^f,g   George, Jacob ^f   Grebely, Jason ^h   Drummer, Heidi E ^a,b,e   Hellard, Margaret ^a,b  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c CURTIN UNIVERSITY   (Australia)

^d VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AUSTRALIA; COHORT ANALYSIS; DRUG ABUSE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PROSPECTIVE STUDY; REINFECTION; VIRAL CLEARANCE; VIREMIA; VIRUS TRANSMISSION;

ADULT; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNITY, INNATE; MALE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; REMISSION, SPONTANEOUS; RISK FACTORS; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84892421965     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080216     Document Type: Article

References (43)

1. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C. Lancet Infect Dis 5: 558-567. doi:10.1016/S1473-3099(05)70216-4. PubMed: 16122679.
2. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW et al. (2012) The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007. Ann Intern Med 156: 271-278. doi: 10.7326/0003-4819-156-4-201202210-00004. PubMed: 22351712.
3. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C (2008) Meta-Regression of Hepatitis C Virus Infection in Relation to Time Since Onset of Illicit Drug Injection: The Influence of Time and Place. Am J Epidemiol 168: 1099-1109. doi:10.1093/aje/kwn237. PubMed: 18849303.
4. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D et al. (2011) Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378: 571-583. doi:10.1016/S0140-6736(11) 61097-0. PubMed: 21802134.
5. Micallef JM, Kaldor JM, Dore GJ (2006) Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 13: 34-41. doi:10.1111/j.1365-2893.2005.00651.x. PubMed: 16364080.
6. Torresi J, Johnson D, Wedemeyer H (2011) Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol 54: 1273-1285. doi:10.1002/hep.24536. PubMed: 21236312.
7. Corson S, Greenhalgh D, Palmateer N, Weir A, Hutchinson S (2010) Risk of Hepatitis C virus re-infection following spontaneous viral clearance in injecting drug users: A systematic review. Int J Drug Policy 22: 102-108. PubMed: 21112759.
8. Grebely J, Prins M, Hellard M, Cox AL, Osburn WO et al. (2012) Towards a hepatitis C virus vaccine: insights from studies of hepatitis C virus reinfection in injection drug users. Lancet Infect Dis 12: 408-414. doi:10.1016/S1473-3099(12)70010-5. PubMed: 22541630.
9. Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS et al. (2008) High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 48: 1746-1752. doi:10.1002/hep.22534. PubMed: 18844233.
10. Micallef JM, Macdonald V, Jauncey M, Amin J, Rawlinson W et al. (2007) High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 14: 413-418. doi:10.1111/j.1365-2893.2006.00812.x. PubMed: 17501762.
11. van de Laar TJW, Molenkamp R, van den Berg C, Schinkel J, Beld MGHM et al. (2009) Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam.[see comment]. J Hepatol 51: 667-674
12. Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L et al. (2010) Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 138: 315-324. doi: 10.1053/j.gastro.2009.09.017. PubMed: 19782080.
13. Page K, Hahn JA, Evans J, Shiboski S, Lum P et al. (2009) Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 200: 1216-1226. doi:10.1086/605947. PubMed: 19764883.
14. Pham ST, Bull RA, Bennett JM, Rawlinson WD, Dore GJ et al. (2010) Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology 52: 1564-1572. doi:10.1002/hep.23885. PubMed: 21038409.
15. Grebely J, Conway B, Raffa JD, Lai C, Krajden M et al. (2006) Hepatitis C virus reinfection in injection drug users.[see comment]. Hepatology 44: 1139-1145
16. Currie SL, Ryan JC, Tracy D, Wright TL, George S et al. (2008) A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. [Erratum appears in Drug Alcohol Depend (2008 Jul);96(1-2): 192]. Drug Alcohol Depend 93: 148-154.
17. McDonald SA, Hutchinson SJ, Cameron SO, Innes HA, McLeod A et al. (2012) Examination of the risk of reinfection with hepatitis C among injecting drug users who have been tested in Glasgow. Int J Drug Policy 23: 353-357. doi:10.1016/j.drugpo.2012.02.003. PubMed: 22421553.
18. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q et al. (2002) Protection against persistence of hepatitis C. Lancet 359: 1478-1483. doi:10.1016/S0140- 6736(02)08435-0. PubMed: 11988247.
19. Vickerman P, Grebely J, Dore GJ, Sacks-davis R, Page K et al. (2012) The more you look the more you find - Effects of hepatitis C virus testing interval on re-infection incidence and clearance: Implications for future vaccine study design. J Infect Dis 205: 1342-1350. doi:10.1093/infdis/jis213. PubMed: 22457292.
20. Page K, Osburn W, Evans J, Hahn JA, Lum P et al. (2013) Frequent Longitudinal Sampling of Hepatitis C Virus Infection in Injection Drug Users Reveals Intermittently Detectable Viremia and Reinfection. Clin Infect Dis 56: 405-413. doi:10.1093/cid/cis921. PubMed: 23090930.
21. McCaw R, Moaven L, Locarnini SA, Bowden DS (1997) Hepatitis C virus genotypes in Australia. J Viral Hepat 4: 351-357. doi:10.1046/j.1365-2893.1997. 00060.x. PubMed: 9310934.
22. Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W (2002) Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 36: 1259-1265. doi:10.1053/jhep.2002.36781. PubMed: 12395338.
23. Miller ER, Hellard ME, Bowden S, Bharadwaj M, Aitken CK (2009) Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia. J Infect 58: 375-382. doi: 10.1016/j.jinf.2009.02.014. PubMed: 19328555.
24. Cox AL, Netski DM, Mosbruger T, Sherman SG, Strathdee S et al. (2005) Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis 40: 951-958. doi: 10.1086/428578. PubMed: 15824985.
25. Busch MP (2001) Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. Transfus Clin Biol 8: 200-206. doi: 10.1016/S1246-7820(01)00125-2. PubMed: 11499958.
26. Page-Shafer K, Pappalardo BL, Tobler LH, Phelps BH, Edlin BR et al. (2008) Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol 46: 499-506. doi:10.1128/JCM.01229-07. PubMed: 18032621.
27. Kelly PJ, Lim LL-Y (2000) Survival analysis for recurrent event data: an application to childhood infectious diseases. Stat Med 19: 13-33. doi: 10.1002/(SICI)1097-0258(20000115)19:1. PubMed: 10623910.
28. Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR (2001) Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 34: 180-187. doi:10.1016/S0168-8278(01)80660-7. PubMed: 11431749.
29. Judd A, Hutchinson S, Wadd S, Hickman M, Taylor A et al. (2005) Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. J Viral Hepat 12: 655-662. doi:10.1111/j.1365-2893.2005.00643.x. PubMed: 16255768.
30. Pouget ER, Hagan H, Des Jarlais DC (2012) Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction 107: 1057-1065. doi:10.1111/j.1360-0443.2011.03765.x. PubMed: 22168373.
31. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E et al. (2002) Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 186: 1558-1564. doi: 10.1086/345554. PubMed: 12447730.
32. Halliday J, Klenerman P, Barnes E (2011) Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines 10: 659-672. doi:10.1586/erv.11.55. PubMed: 21604986.
33. Backmund M, Meyer K, Edlin BR (2004) Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 39: 1540-1543. doi:10.1086/425361. PubMed: 15546094.
34. Dalgard O, Bjøro K, Hellum K, Myrvang B, Skaug K et al. (2002) Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 8: 45-49. doi:10.1159/000049487. PubMed: 11818693.
35. Grebely J, Pham ST, Matthews GV, Petoumenos K, Bull RA et al. (2012) Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology 55: 1058-1069. doi:10.1002/hep.24754. PubMed: 22031335.
36. Grady BPX, Vanhommerig JW, Schinkel J, Weegink CJ, Bruisten SM et al. (2012) Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam. Eur J Gastroenterol Hepatol 24: 1302-1307. PubMed: 22825643.
37. Grebely J, Knight E, Ngai T, Genoway KA, Raffa JD et al. (2010) Reinfection with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol 25: 1281-1284. doi:10.1111/j.1440-1746.2010.06238.x. PubMed: 20594256.
38. Marco A, Esteban JI, Solé C, da Silva A, Ortiz J et al. (2013) Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol 59: 45-51. doi: 10.1016/j.jhep.2013.03.008. PubMed: 23523577.
39. Doyle JS, Aspinall E, Liew D, Thompson AJ, Hellard ME (2013) Current and emerging antiviral treatments for hepatitis C infection. Br J Clin Pharmacol 75: 931-943. doi:10.1111/j.1365-2125.2012.04419.x.PubMed: 22882367.
40. Gyarmathy VA, Li N, Tobin KE, Hoffman IF, Sokolov N et al. (2010) Injecting Equipment Sharing in Russian Drug Injecting Dyads. AIDS Behav 14: 141-151. doi:10.1007/s10461-008-9518-6. PubMed: 19214731.
41. Craine N, Hickman M, Parry JV, Smith J, Walker AM et al. (2009) Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiol Infect 137: 1255-1265. doi:10.1017/S095026880900212X.PubMed: 19224654.
42. Marufu M, Williams H, Hill SL, Tibble J, Verma S (2012) Gender differences in hepatitis C seroprevalence and suboptimal vaccination and hepatology services uptake amongst substance misusers. J Med Virol 84: 1737-1743. doi:10.1002/jmv.23389. PubMed: 22997076.
43. Stoové MA, Gifford SM, Dore GJ (2005) The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend 77: 81-86. doi:10.1016/j.drugalcdep.2004.07.002. PubMed: 15607844.